Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC41 DDI and PK/Safety Study in Healthy Volunteers and NAFLD
NCT04845646Phase 1Completed
- Sponsor
- Gannex Pharma Co., Ltd.
- Start
- Mar 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ASC-41 in non-alcoholic fatty liver disease (NAFLD) (3 arms), sponsored by Gannex Pharma Co., Ltd. Primary endpoints: Area Under the Curve of ASC41 up to 24 days and Peak Plasma Concentration of ASC41 up to 24 days. Started Mar 2021; status: completed.
02
Drugs
ASC-41
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT04845646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04845646.